跳至主要内容
临床试验/EUCTR2005-000163-25-GB
EUCTR2005-000163-25-GB进行中(未招募)1 期

Proteomics and Pharmacokinetics of Adriamycin Following Different Techniques for Chemoembolisation of Hepatocellular Carcinoma (PPATCH) Trial - PPATCH

Research and Enterprise, University of Birmingham0 个研究点目标入组 20 人开始时间: 2005年5月4日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Fulfil criteria for diagnosis of HCC:
  • At least one of the following need to be met for diagnosis
  • I.Liver mass with histological confirmation of biopsied sample
  • II.Liver mass with AFP>500
  • III. Liver mass with evidence of chronic Hepatitis C with or with out cirrhosis
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Extensive disease
  • a.Multi-focal disease of greater than 4 lesions in either lobe
  • b.Metastatic disease
  • 2.Renal failure: GFR<60
  • 3.Liver Function: No history of Encephalopathy, No ascites not easily medically controlled, Albumin>30, Bilirubin<50, If INR>1.2 administer 10mg vitamin K needs to be <1.5 to proceed
  • 4.FBC: WCC<3.0, Neutophils<1.5, platelets<60
  • 5.Performance status >2
  • 6.Presence of vascular invasion-(including segmental portal obstruction)
  • 7.Contraindication to Doxorubicin:
  • a.Ejection fraction<50%
  • b.Hypersensitivity to hydroxybenzoates
  • c.Buccal ulceration
  • 8.Portosystemic shunt i.e. for oesophageal varicies,
  • 9.GI bleed
  • 10.Severe artheromatosis
  • 11.Previous biliary surgery

研究者

发起方
Research and Enterprise, University of Birmingham

相似试验